Renin-angiotensin polymorphisms and QTc interval prolongation in end-stage renal disease

Kidney International

Volumn 68, Issue 3, 2005, Pages 1186-1189

  Raizada, Veena ^a   Skipper, Betty ^b   Luo, Wentao ^b   Garza, Luis ^b   Hines, Curt W ^b   Harford, Antonia A ^b   Zager, Philip G ^b   Griffith, Jeffrey ^b   Raj, Dominic ^b   Spalding, Charles T ^b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

ESRD; Qtc; RAS

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSINOGEN; CALCIUM; DIPEPTIDYL CARBOXYPEPTIDASE; POTASSIUM; RAS PROTEIN; SODIUM;

ADULT; AGED; ALLELE; ARTICLE; CARDIOVASCULAR RISK; CHEEK; CLINICAL ARTICLE; ELECTROCARDIOGRAM; ELECTROLYTE BLOOD LEVEL; FEMALE; GENE DELETION; GENE INSERTION; GENETIC POLYMORPHISM; GENOTYPE; HEART DEATH; HEART RATE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; QRS COMPLEX; QT INTERVAL; QT PROLONGATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINUS RHYTHM;

ADULT; AGED; ANGIOTENSINOGEN; DEATH, SUDDEN, CARDIAC; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KIDNEY FAILURE, CHRONIC; LONG QT SYNDROME; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; PREVALENCE; RECEPTOR, ANGIOTENSIN, TYPE 1; RENAL DIALYSIS; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 32644474968     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00510.x     Document Type: Article

References (35)

1. US RENAL DATA SYSTEM, USRDS 2004 ANNUAL DATA REPORT: Atlas of End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2004
2. LAZARUS JM, BRENNER BM: Chronic renal failure, in Harrison's Principles of Internal Medicine, edited by Fauci AS, Braunwald E, Isselbacher K, et al, New York, McGraw-Hill, 2001, pp 1513-1520
3. RAJ DS, ZAGER P, SHAH VO, et al: Protein turnover and amino acid transport kinetics in end-stage renal disease. Am J Physiol Endocrinol Metab 286:E136-E143, 2004
4. DONOHOE P, HENDRY BM, WALGAMA OV, et al: An altered repolarizing potassium current in rat cardiac myocytes after subtotal nephrectomy. J Am Soc Nephrol 11:1589-1599, 2000
5. JERON A, HENGSTENBERG C, ENGEL S, et al: The D-allele of the ACE polymorphism is related to increased QT dispersion in 609 patients after myocardial infarction. Eur Heart J 22:663-668, 2001
6. ANVARI A, TUREL Z, SCHMIDT A, et al: Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphism in coronary disease and malignant ventricular arrhythmias. Cardiovasc Res 43:879-883, 1999
7. RIGAT B, HUBERT C, ALHENC-GELAS F, et al: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86:1343-1346, 1990
8. BONNARDEAUX A, DAVIES E, JEUNEMAITRE X, et al: Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 24:63-69, 1994
9. SCHUNKERT H: Polymorphism of the angiotensin-converting enzyme gene and cardiovascular disease. J Mol Med 75:867-875, 1997
10. FOMICHEVA EV, GUKOVA SP, LARIONOVA-VASINA VI, et al: Gene-gene interaction in the RAS system in the predisposition to myocardial infarction in elder population of St. Petersburg (Russia). Mol Genet Metab 69:76-80, 2000
11. MORGANROTH J: A definitive or thorough phase 1 QT ECG trial as a requirement for drug safety assessment. J Electrocardiol 37:25-29, 2004
12. LUO S, MICHLER K, JOHNSTON P, MACFARLANE PW: A comparison of commonly used QT correction formulae: The effect of heart rate on the QTc of normal ECGs. J Electrocardiol 37:81-90, 2004
13. MIRVIS DM, GOLDBERGER AL: Electrocardiography, in Heart Disease, edited by Braunwald E, Zipes DP, Libby P, Philadelphia, WB Saunders Company, 2001, pp 82-126
14. PAPP F, FRIEDMAN AL, BERECZKI C, et al: Renin-angiotensin gene polymorphism in children with uremia and essential hypertension. Pediatr Nephrol 18:150-154, 2003
15. JENG JR: Left ventricular mass, carotid wall thickness, and angiotensinogen gene polymorphism in patients with hypertension. Am J Hypertens 12:443-450, 1999
16. LUM A, LE MARCHAND L: A simple mouthwash method for obtaining genomic DNA in molecular epidemiological studies. Cancer Epidemiol Biomarkers Prev 7:719-724, 1998
17. OLGIN JE, ZIPES DP: Specific arrhythmias: Diagnosis and treatment, in Heart Disease, edited by Braunwald E. Zipes DP, Libby P, Philadelphia, WB Saunders Company, 2001, pp 869-871
18. MORRIS STW, GALIATSOU E, STEWART GA, et al: QT dispersion before and after hemodialysis. J Am Soc Nephrol 10:160-163, 1999
19. LORINCZ I, MATYUS J, ZILAHI Z, et al: QT dispersion in patients with end-stage renal failure and during hemodialysis. J Am Soc Nephrol 10:1297-1302, 1999
20. NAPPI SE, VIRTANEN VK, SAHA HHT, et al: QTc dispersion increases during hemodialysis with low-calcium dialysate. Kidney Int 57:2117-2122, 2000
21. GENOVESI S, RIVERA R, FABBRINI P, et al: Dynamic QT interval analysis in uraemic patients receiving chronic haemodialysis. J Hypertens 21:1921-1926, 2003
22. COVIC A, DIACONITA M, GUSBETH-TATOMIR P, et al: Haemodialyisis increases QTc interval but not QTc dispersion in ESRD patients without manifest cardiac disease. Nephrol Dial Transplant 17:2170-2177, 2002
23. CUPISTI A, GALETTA F, MORELLI E, et al: Effect of hemodialysis on the dispersion of the QTc interval. Nephron 78:429-432, 1998
24. SHAPIRA OM, BAR-KHAYIM Y: ECG changes and cardiac arrhythmias in chronic renal failure patients on hemodialysis. J Electrocardiol 25:273-279, 1992
25. EREM C, KULAN K, GOLDELI O, et al: Impact of hemodialysis on QT interval. Acta Cardiologica L:177-185, 1995
26. MAULE S, VEGLIO M, MECCA F, et al: Autonomic neuropathy and QT interval in hemodialysed patients. Clin Auton Res 14:233-239, 2004
27. TAKAHASHI T, UENO H, YASUMOTO K, et al: Angiotensin-converting enzyme-gene polymorphism is associated with collagen I synthesis and QT dispersion in essential hypertension. Hypertension 21:985-991, 2003
28. YAN GX, RIALS SJ, WU Y, et al: Ventricular hypertrophy amplifies transmural repolarization dispersion and induces early afterdepolarization. Am J Physiol Heart Circ Physiol 281:H1968-H1975, 2001
29. SHIMONI Y: Inhibition of the formation or action of angiotensin II reverses attenuated K+ currents in type 1 and type 2 diabetes. J Physiol 537:83-92, 2001
30. KULMATYCKI KM, ABOUCHEHADE K, SATTARI S, JAMALI F: Drug-disease interactions: Reduced beta-adrenergic and potassium channel antagonist activities of sotalol in the presence of acute and chronic inflammatory conditions in the rat. Br J Pharmacol 133:286-294, 2001
31. SWYNGHEDAUW B, BAILLARD C, MILLIEZ P: The long QT interval is not only inherited but is also linked to cardiac hypertrophy. J Mol Med 81:336-345, 2003
32. GUO W, KAMIYA K, YASUI K, et al: Paracrine hypertrophic factors from cardiac non-myocyte cells downregulate the transient outward current density and Kv4.2 K+ channel expression in cultured rat cardiomyocytes. Cardiovasc Res 41:157-175, 1999
33. DE MELLO WC: Cardiac arrhythmias: the possible role of the renin-angiotensin system. J Mol Med 79:103-108, 2001
34. DOSTAL DE: The cardiac renin-angiotensin system: Novel signaling mechanisms related to cardiac growth and function. Regulatory Peptides 91:1-11, 2000
35. DALEAU P, TURGEON J: Angiotensin II modulates the delayed rectifier potassium current of guinea pig ventricular myocytes. Pflugers Arch 427:553-555, 1994